...
首页> 外文期刊>Current drug delivery >Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production
【24h】

Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production

机译:制药行业中的纳米颗粒以及超临界流体技术在纳米颗粒生产中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Poor aqueous solubility of drug candidates is a major challenge for the pharmaceutical scientists involved in drug development. Particle size reduction appears as an effective and versatile option for solubility improvement. Nanonization is an attractive solution to improve the bioavailability of the poorly soluble drugs, improved therapies, in vivo imaging, in vitro diagnostics and for the production of biomaterials and active implants. In drug delivery, application of nanotechnology is commonly referred to as Nano Drug Delivery Systems (NDDS). In this article, commercially available nanosized drugs, their dosage forms and proprietors, as well as the methods used for preparation like milling, high pressure homogenization, vacuum deposition, and high temperature evaporation were listed. Unlike the traditional methods used for the particle size reduction, supercritical fluid-processing techniques offer advantages ranging from superior particle size control to clean processing. The primary focus of this review article is the use of supercritical CO 2 based technologies for small particle generation. Particles that have the smooth surfaces, small particle size and distribution and free flowing can be obtained with particular SCF techniques. In almost all techniques, the dominating process variables may be thermodynamic and aerodynamic in nature, and the design of the particle collection environment. Rapid Expansion of Supercritical Solutions (RESS), Supercritical Anti Solvent (SAS) and Particles from Gas Saturated Solutions (PGSS) are three groups of processes which lead to the production of fine and monodisperse powders. Few of them may also control crystal polymorphism. Among the aforementioned processes, RESS involves dissolving a drug in a supercritical fluid (SCF) and passing it through an appropriate nozzle. Rapid depressurization of this solution causes an extremely rapid nucleation of the product. This process has been known for a long time but its application is limited. Carbon dioxide, which is the only supercritical fluid that is preferentially used in pharmaceutical processes, is not a good solvent for many Active Pharmaceutical Ingredients (API). Various researchers have modified the RESS process to overcome its solubilizing limitations, by introducing RESOLV, RESAS, and RESS-SC. Overall, all RESS based processes are difficult to scale up. The SAS processes are based on decreasing the solvent power of a polar organic solvent in which the substrate (API & polymer of interest) is dissolved, by saturating it with carbon dioxide (CO 2) at supercritical conditions. CO 2 causes precipitation and recrystalization of the drug. SAS is scalable and can be applied to a wide variety of APIs and polymers. Minor modifications of basic SAS process include GAS, ASES, SAS-DEM and SAS-EM. Processes where SCF is used as an anti solvent and dispersing agent include SEDS, SAA, and A-SAIS. The mechanisms and applications of these processes were briefly discussed. In PGSS, CO 2 is dissolved in organic solutions or melted compounds and it is successfully used for manufacturing drug products as well as for drying purposes. The two widely used methods, PGSS-drying and CAN-BD SCF, were also included in discussions. Among the limitations of the techniques involved, the poor solvent power of CO 2, the cost and necessity of voluminous usage of the CO 2 can be mentioned. There is still confusion in contribution of each variable on the particle morphology and properties regardless of the number of mechanistic studies available. The advantages of especially SAS and PGSS based techniques are the production of the nano or micro sized spherical particles with smooth surfaces and narrow particle size distribution. Regardless of its advantages, the reasons why 25 years of active research, and more than 10 years of process development could not promote the use of (SCF) technology, and produced only few commercial drug products, necessitate further
机译:候选药物的水溶性差是参与药物开发的药物科学家的主要挑战。减小粒度似乎是提高溶解度的有效且通用的选择。 Nanonization是一种吸引人的解决方案,可改善难溶性药物的生物利用度,改善疗法,体内成像,体外诊断以及生产生物材料和活性植入物。在药物输送中,纳米技术的应用通常称为纳米药物输送系统(NDDS)。在本文中,列出了市售的纳米级药物,其剂型和所有人以及用于制备的方法,如研磨,高压均质化,真空沉积和高温蒸发。与用于减小粒度的传统方法不同,超临界流体处理技术具有从优异的粒度控制到清洁处理的优势。本文的主要重点是基于超临界CO 2的技术用于小颗粒的产生。可以使用特定的SCF技术获得具有光滑表面,小粒径和分布以及自由流动的颗粒。在几乎所有技术中,主要的过程变量在本质上可能是热力学和空气动力学,并且在粒子收集环境的设计上也可能如此。超临界溶液(RESS),超临界抗溶剂(SAS)和气体饱和溶液(PGSS)中的颗粒的快速膨胀是导致生产细粉和单分散粉体的三类过程。他们中很少有人也可以控制晶体多态性。在上述过程中,RESS涉及将药物溶解在超临界流体(SCF)中并使其通过适当的喷嘴。该溶液的快速降压导致产物非常迅速的成核。这个过程早已为人所知,但其应用受到限制。二氧化碳是优先用于制药工艺的唯一超临界流体,对于许多活性药物成分(API)而言,它并不是良好的溶剂。通过引入RESOLV,RESAS和RESS-SC,许多研究人员已经修改了RESS工艺以克服其溶解性限制。总体而言,所有基于RESS的流程都难以扩展。 SAS工艺基于通过在超临界条件下用二氧化碳(CO 2)使其饱和来降低溶解了底物(API和目标聚合物)的极性有机溶剂的溶剂能力。 CO 2引起药物沉淀和重结晶。 SAS是可扩展的,可以应用于多种API和聚合物。基本SAS流程的较小修改包括GAS,ASES,SAS-DEM和SAS-EM。将SCF用作抗溶剂和分散剂的过程包括SEDS,SAA和A-SAIS。简要讨论了这些过程的机制和应用。在PGSS中,CO 2溶解在有机溶液或熔融的化合物中,并且已成功用于制造药品和干燥目的。讨论中还包括两种广泛使用的方法,PGSS干燥和CAN-BD SCF。在所涉及的技术的局限性中,可以提到CO 2的溶剂能力差,成本和大量使用CO 2的必要性。无论可用的机械研究数量如何,每个变量对颗粒形态和性能的贡献仍然存在混淆。特别是基于SAS和PGSS的技术的优势在于,可以生产出具有光滑表面和窄粒度分布的纳米或微米级球形颗粒。不论其优势如何,为何25年的积极研究和10多年的工艺开发无法促进(SCF)技术的使用,并且仅生产很少的商业药品的原因,有必要进一步

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号